Byron Hyde: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(typo)
(CS1 error)
Line 16: Line 16:
*2003, Clinical Improvement in [[Chronic fatigue syndrome|Chronic Fatigue Syndrome]] Is Associated with Enhanced [[Natural killer cell|Natural Killer Cell]]-Mediated [[Cytotoxicity]]: The Results of a Pilot Study with Isoprinosine®<ref>{{Cite journal|last=Diaz-Mitoma|first=Francisco|author-link=|last2=Turgonyi|first2=Eva|author-link2=|last3=Kumar|first3=Ashok|author-link3=|last4=Lim|first4=Wilfred|author-link4=|last5=Larocque|first5=Louise|author-link5=|last6=Hyde|first6=Byron M.|author-link6=Byron Hyde|date=Jan 2003|title=Clinical Improvement in Chronic Fatigue Syndrome Is Associated with Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine®|url=http://www.tandfonline.com/doi/full/10.1300/J092v11n02_06|journal=Journal of Chronic Fatigue Syndrome|language=en|volume=11|issue=2|pages=71–95|doi=10.1300/J092v11n02_06|issn=1057-3321|quote=|via=}}</ref> [http://dx.doi.org/10.1300/J092v11n02_06 (Abstract)]
*2003, Clinical Improvement in [[Chronic fatigue syndrome|Chronic Fatigue Syndrome]] Is Associated with Enhanced [[Natural killer cell|Natural Killer Cell]]-Mediated [[Cytotoxicity]]: The Results of a Pilot Study with Isoprinosine®<ref>{{Cite journal|last=Diaz-Mitoma|first=Francisco|author-link=|last2=Turgonyi|first2=Eva|author-link2=|last3=Kumar|first3=Ashok|author-link3=|last4=Lim|first4=Wilfred|author-link4=|last5=Larocque|first5=Louise|author-link5=|last6=Hyde|first6=Byron M.|author-link6=Byron Hyde|date=Jan 2003|title=Clinical Improvement in Chronic Fatigue Syndrome Is Associated with Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine®|url=http://www.tandfonline.com/doi/full/10.1300/J092v11n02_06|journal=Journal of Chronic Fatigue Syndrome|language=en|volume=11|issue=2|pages=71–95|doi=10.1300/J092v11n02_06|issn=1057-3321|quote=|via=}}</ref> [http://dx.doi.org/10.1300/J092v11n02_06 (Abstract)]
*2007, [[Thyroid gland|Thyroid]] malignancy association with cortical & subcortical brain [[SPECT]] changes in patients presenting with a myalgic encephalomyelitis / Chronic Fatigue Syndrome<ref>{{Cite journal|last=Hyde|first=Byron|author-link=Byron Hyde|last2=Leveille|first2=Jean|author-link2=|last3=Vaudrey|first3=Sheila|author-link3=|last4=Green|first4=Tracy|author-link4=|author-link5=|date=2007|title=Thyroid malignancy association with cortical & subcortical brain SPECT changes in patients presenting with a myalgic encephalomyelitis/Chronic Fatigue Syndrome|url=https://inis.iaea.org/search/search.aspx?orig_q=RN:38097156|journal=ALASBIMN Journal|volume=38|issue=42|pages=18|quote=|via=}}</ref> [https://inis.iaea.org/search/search.aspx?orig_q=RN:38097156 (Abstract)]
*2007, [[Thyroid gland|Thyroid]] malignancy association with cortical & subcortical brain [[SPECT]] changes in patients presenting with a myalgic encephalomyelitis / Chronic Fatigue Syndrome<ref>{{Cite journal|last=Hyde|first=Byron|author-link=Byron Hyde|last2=Leveille|first2=Jean|author-link2=|last3=Vaudrey|first3=Sheila|author-link3=|last4=Green|first4=Tracy|author-link4=|author-link5=|date=2007|title=Thyroid malignancy association with cortical & subcortical brain SPECT changes in patients presenting with a myalgic encephalomyelitis/Chronic Fatigue Syndrome|url=https://inis.iaea.org/search/search.aspx?orig_q=RN:38097156|journal=ALASBIMN Journal|volume=38|issue=42|pages=18|quote=|via=}}</ref> [https://inis.iaea.org/search/search.aspx?orig_q=RN:38097156 (Abstract)]
*2011, TCP (tricresyl phosphate): pilot, aircrew and passenger safety and secondary myalgic encephalomyelitis<ref>{{Cite journal|last=Hyde|first=Byron M.|author-link=Byron Hyde|author-link2=|author-link3=|author-link4=|author-link5=|date=2011|title=TCP (tricresyl phosphate): pilot, aircrew and passenger safety and secondary myalgic
*2011, TCP (tricresyl phosphate): pilot, aircrew and passenger safety and secondary myalgic encephalomyelitis<ref>{{Cite journal|last=Hyde|first=Byron M.|author-link=Byron Hyde|author-link2=|author-link3=|author-link4=|author-link5=|date=2011|title=TCP (tricresyl phosphate): pilot, aircrew and passenger safety and secondary myalgic encephalomyelitis|url=http://www.itcoba.net/29HY11A.pdf|journal=Journal of Biological Physics and Chemistry|volume=11|issue=|pages=172-179|quote=|via=}}</ref> [http://www.itcoba.net/29HY11A.pdf (Full text)]
encephalomyelitis|url=http://www.itcoba.net/29HY11A.pdf|journal=Journal of Biological Physics and Chemistry|volume=11|issue=|pages=172-179|quote=|via=}}</ref> [http://www.itcoba.net/29HY11A.pdf (Full text)]


==Clinic location==
==Clinic location==

Revision as of 20:59, March 23, 2019

Source:mevereniging.nl

Dr. Bryon Marshall Hyde is a family practice physician in Ottawa, Canada, who has dedicated his practice solely to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) since 1984, after several of his colleagues developed the illness.[1] In 1988, he founded the Nightingale Research Foundation, which is committed to exploring and understanding myalgic encephalomyelitis (ME), chronic fatigue syndrome (CFS), and fibromyalgia-type illnesses.[2]

Dr. Hyde has traveled extensively to study ME and examine patients, spending time at: the Centers for Disease Control and Prevention (CDC), in Atlanta, US; Beth Israel Deaconess Medical Center, Boston, US; the UK; Australia; New Zealand; and Akureyri, Iceland.[1][2]

In 1991, Dr. Hyde organized the first World Symposium on M.E. at Cambridge University in collaboration with Dr. John Richardson and the Newcastle Research Group in the UK.[2]

Education[edit | edit source]

  • 1961, University of Toronto in Food Chemistry and Nutrition[3]
  • 1966, MD - University of Ottawa’s Faculty of Medicine[2][3]
  • Internship at Hôtel-Dieu de Montréal in Neuro and Vascular Surgery[3]
  • Residency at the St. Justine Paediatric Hospital and the Ottawa Civic Hospital[2][3]

Notable studies[edit | edit source]

Clinic location[edit | edit source]

Nightingale Research Foundation
121 Iona Street, Ottawa Ontario K1Y 3M1, Canada
info@nightingale.ca

Talks & interviews[edit | edit source]

Books and book chapters[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved March 6, 2019. Cite has empty unknown parameter: |dead-url= (help)
  2. 2.0 2.1 2.2 2.3 2.4 "Our Founder | Nightingale Research Foundation". nightingale.ca. Retrieved March 23, 2019. Cite has empty unknown parameter: |dead-url= (help)
  3. 3.0 3.1 3.2 3.3 "CURRICULUM VITAE" (PDF). Retrieved March 23, 2019. Cite has empty unknown parameter: |dead-url= (help)
  4. Diaz-Mitoma, Francisco; Turgonyi, Eva; Kumar, Ashok; Lim, Wilfred; Larocque, Louise; Hyde, Byron M. (January 2003). "Clinical Improvement in Chronic Fatigue Syndrome Is Associated with Enhanced Natural Killer Cell-Mediated Cytotoxicity: The Results of a Pilot Study with Isoprinosine®". Journal of Chronic Fatigue Syndrome. 11 (2): 71–95. doi:10.1300/J092v11n02_06. ISSN 1057-3321.
  5. Hyde, Byron; Leveille, Jean; Vaudrey, Sheila; Green, Tracy (2007). "Thyroid malignancy association with cortical & subcortical brain SPECT changes in patients presenting with a myalgic encephalomyelitis/Chronic Fatigue Syndrome". ALASBIMN Journal. 38 (42): 18.
  6. Hyde, Byron M. (2011). "TCP (tricresyl phosphate): pilot, aircrew and passenger safety and secondary myalgic encephalomyelitis" (PDF). Journal of Biological Physics and Chemistry. 11: 172–179.
  7. http://www.investinme.eu/IIMEC1.shtml#agenda
  8. http://www.investinme.eu/IIMEC2.shtml#agenda
  9. Handbook of chronic fatigue syndrome. Jason, Leonard, Fennell, Patricia, Taylor, Renée R. Hoboken, N.J.: Wiley. 2003. ISBN 047141512X. OCLC 50693363.CS1 maint: others (link)